Blood Reviews
Volume 22, Issue 5 , Pages 235-245 , September 2008

Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy

  • Martin Griesshammer

      Affiliations

    • Department of Medicine III, Robert-Koch-Strasse 8, D-89081 Ulm, Federal Republic of Germany
    • Corresponding Author InformationCorresponding author. Tel.: +49 731 5002 4485; fax: +49 731 502 4405.
    • ,
  • Sabine Struve

      Affiliations

    • Department of Medicine III, Robert-Koch-Strasse 8, D-89081 Ulm, Federal Republic of Germany
    • ,
  • Tiziano Barbui

      Affiliations

    • Divisione di Ematologia, Ospedali Riuniti, Largo Barozzi 1, 24100 Bergamo, Italy

References 

  1. Bates SM, Ginsberg JS. Thrombosis in pregnancy. Curr Opin Hematol. 1997;4:335–343
  2. Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005;129:293–306
  3. Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost. 2006;32:422–429
  4. Taylor UB, Bardeguez AD, Iglesias N, Gascon P. Idiopathic myelofibrosis in pregnancy: a case report and review of the literature. Am J Obstet Gynecol. 1992;167:38–39
  5. Gotic M, Cvetkovic M, Bozanovic T, Cemerikic V. [Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon]. Srp Arh Celok Lek. 2001;129:304–308
  6. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–2168
  7. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110:1092–1097
  8. Johansson P, Kutti J, Andreasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983–99. J Intern Med. 2004;256:161–165
  9. Nelson SM, Greer IA. Thrombophilia and the risk for venous thromboembolism during pregnancy, delivery, and puerperium. Obstet Gynecol Clin North Am. 2006;33:413–427
  10. Richter R, Bergmann RL, Dudenhausen JW. Previous caesarean or vaginal delivery: which mode is a greater risk of perinatal death at the second delivery?. Eur J Obstet Gynecol Reprod Biol. 2007;132:51–57
  11. Gunter HH, Scharf A, Hillemanns P, Wenzlaff P, Maul H. [Pregnancies without prenatal care–which women are potentially affected, what are the inherent fetal risks?]. Z Geburtshilfe Neonatol. 2007;211:27–32
  12. Finazzi G, Harrison C. Essential thrombocythemia. Semin Hematol. 2005;42:230–238
  13. Hoagland HC, Silverstein MN. Primary thrombocythemia in the young patient. Mayo Clin Proc. 1978;53:578–580
  14. Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer. 1986;58:2440–2447
  15. Beard J, Hillmen P, Anderson CC, Lewis SM, Pearson TC. Primary thrombocythaemia in pregnancy. Br J Haematol. 1991;77:371–374
  16. Leone G, De Stefano V, D’Addosio A. [Essential thrombocythemia: pregnancy]. Haematologica. 1991;76(Suppl 3):365–367
  17. Beressi AH, Tefferi A, Silverstein MN, Petitt RM, Hoagland HC. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med. 1995;155:1217–1222
  18. Pagliaro P, Arrigoni L, Muggiasca ML, Poggio M, Russo U, Rossi E. Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. Am J Hematol. 1996;53:6–10
  19. Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies. J Intern Med. 1999;246:517–518
  20. Bangerter M, Guthner C, Beneke H, Hildebrand A, Grunewald M, Griesshammer M. Pregnancy in essential thrombocythaemia: treatment and outcome of 17 pregnancies. Eur J Haematol. 2000;65:165–169
  21. Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol. 2001;66:152–159
  22. Niittyvuopio R, Juvonen E, Kaaja R, et al. Pregnancy in essential thrombocythaemia: experience with 40 pregnancies. Eur J Haematol. 2004;73:431–436
  23. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110:485–489
  24. Griesshammer M. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost. 2006;32:372–380
  25. Chow EY, Haley LP, Vickars LM. Essential thrombocythemia in pregnancy: platelet count and pregnancy outcome. Am J Hematol. 1992;41:249–251
  26. Sejeny SA, Eastham RD, Baker SR. Platelet counts during normal pregnancy. J Clin Pathol. 1975;28:812–813
  27. Griesshammer M, Grunewald M, Michiels JJ. Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost. 2003;29:205–212
  28. Griesshammer M, Bergmann L, Pearson T. Fertility, pregnancy and the management of myeloproliferative disorders. Baillieres Clin Haematol. 1998;11:859–874
  29. Cincotta R, Higgins JR, Tippett C, et al. Management of essential thrombocythaemia during pregnancy. Aust N Z J Obstet Gynaecol. 2000;40:33–37
  30. Griesshammer M, Heimpel H, Pearson TC. Essential thrombocythemia and pregnancy. Leuk Lymphoma. 1996;22(Suppl 1):57–63
  31. Hunt BJ, Gattens M, Khamashta M, Nelson-Piercy C, Almeida A. Thromboprophylaxis with unmonitored intermediate-dose low molecular weight heparin in pregnancies with a previous arterial or venous thrombotic event. Blood Coagul Fibrinolysis. 2003;14:735–739
  32. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81:668–672
  33. Martinelli P, Martinelli V, Agangi A, et al. Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gynecol. 2004;191:2016–2020
  34. Asano Y, Okaniwa A. In utero morphological effects of hydroxyurea on the fetal development in Sprague-Dawley rats. Jikken Dobutsu. 1987;36:143–149
  35. Perez-Encinas M, Bello JL, Perez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol. 1994;46:225–229
  36. Falconer J, Pineo G, Blahey W, Bowen T, Docksteader B, Jadusingh I. Essential thrombocythemia associated with recurrent abortions and fetal growth retardation. Am J Hematol. 1987;25:345–347
  37. Mercer B, Drouin J, Jolly E, d’Anjou G. Primary thrombocythemia in pregnancy: a report of two cases. Am J Obstet Gynecol. 1988;159:127–128
  38. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. The management and outcome of 18 pregnancies in women with polycythemia vera. Haematologica. 2005;90:1477–1483

PII: S0268-960X(08)00026-X

doi: 10.1016/j.blre.2008.03.007

Blood Reviews
Volume 22, Issue 5 , Pages 235-245 , September 2008

Article Tools

* Image Usage & Resolution